GIP (1-42)
glucose-dependent insulinotropic polypeptide · human GIP · C226H347N57O67S · monoisotopic 4980.5163 Da. The index holds 0 assay reports on this compound across 0 batches from 0 suppliers.
Analytical fingerprint
Hand-authored chemistry. These properties describe the substance and do not change when a record is added.
The signature impurity in GIP lots is the (3-42) truncate — the DPP-4 product — at −227 Da and only 0.31 min from the main peak. It is poorly resolved and the index requires mass-selective confirmation before accepting a GIP purity figure above 98 %. Its presence in a dry lot indicates enzymatic exposure during purification rather than storage. Coverage is thin (n under 60).
- Compound class
- Incretin analogues and co-agonists
- Molecular formula
- C226H347N57O67S
- Monoisotopic mass
- 4980.5163Da
- Average mass
- 4983.60Da
- Residues
- 42
- Nominal retention (RG-2, 30 min)
- 15.84min
- Retention window
- 0.40min
- Counter-ion as usually shipped
- acetate
- Typical label claims
- 1 mg · 2 mg · 5 mg
- Analytical difficulty (index scale)
- 1.20 — moderate
- Purity is a defined quantity
- YES
What the index has observed
Arithmetic over the 0 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.
The index holds no records for GIP (1-42) carrying a purity figure. That is a gap in the index, not a finding about the compound.
Characteristic impurities and degradants
The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.
| Named species | ΔRT (min, RG-2) | Δ mass (Da) | Seen in | Median % area | Max % area |
|---|---|---|---|---|---|
| GIP (3-42) DPP-4 truncate (−227 Da) | -0.31 | -227.116 | — | not observed | — |
| Met14 sulfoxide (+16 Da) | -0.75 | +15.995 | — | not observed | — |
| deamidated (+1 Da) | -0.40 | +0.984 | — | not observed | — |
| truncated (1-30) | -2.12 | -1379.694 | — | not observed | — |
Degradation pathways
- N-terminal Tyr-Ala cleavage by residual DPP-4 activity in impure aqueous diluent
- Met oxidation
Full impurity profile, with what each named species implies about the synthesis →
Clinical context
Included because it is routinely misapplied. Trial data describes a licensed medicinal product manufactured under a marketing authorisation, and it does not transfer to research-grade material of unknown provenance.
GIP receptor pharmacology is the basis of the dual and triple agonists above; native GIP itself has no approved indication.
Quarterly coverage
Most recent records
No records yet. Submitting one is the only way this changes.